'What's New in Geroscience - What Makes Us Age & Can We Stop It?'
Kindly Sponsored by Merck
King's Hedges & Queen Edith's Rooms, The Cambridge Building, Babraham Research Campus, Cambridge
Tuesday 10 March 2020
'What's New in Geroscience - What Makes Us Age & Can We Stop It?'

About the topic:

Aging is the single greatest challenge for biomedicine in the 21st century, with Geroscience emerging as an interdisciplinary field that seeks to define the genetic, molecular, and cellular mechanisms of aging that gives rise to numerous age-related diseases and disorders.

Over the years, researchers studying the basic science of ageing have sought to answer the question of how the ageing process affects the disease process, and while aging itself isn't a disease, the aging process represents a major risk factor for several chronic diseases and conditions, including frailty and lack of resilience.

It is an exciting time in the field of Geroscience, with recent advances allowing scientists and clinicians, for the first time, to consider interventions aimed at directly targeting the hallmarks of aging and prevent multiple diseases of aging simultaneously.  Our panel of thought leaders and innovators from across the Geroscience space will provide a broad update of research and innovation as well as considering: 

  • - What potential do existing drugs such as metformin and rapamycin have as anti-aging drugs?
  • - Should the destruction of ‘zombie’ cells a target of therapeutics?
  • - How does autophagy fit into the Geroscience space?
  • - As Geroscience is not classified as a disease, what regulatory challenges does this cause?
  • - What is the funding landscape like for clinical trials in this space?
  • - What role does AI play in Geroscience research?

Programme & Speakers:
17.30              Delegate Registration, tea & coffee served
18.00              Welcome by OBN 
18.05              Keynote: Professor Paul Shiels, Professor of Epigenetics at the Institute of Cancer Sciences & Associate Professor at the Institute of Health & Wellbeing, University of Glasgow
18.25              Keynote: from Dr Marina Wiklander, Field Marketing Specialist, Research and Applied Lab Solutions Western Europe at Merck regarding the use of 3D cell technology to understand the pathology of dementia
18.55              Keynote: from Associate Prof. Lynne Cox, Department of Biochemistry at the University of Oxford who will share an update on their study of the molecular and cellular basis of aging
19.15              Company Presentation: Dr Adam de Graff, Senior Scientist, Methuselah Health, who identify novel targets for treatment of aging-related diseases
19.30              Company Presentation: Dr Peter Hamley, CSO at Samsara Therapeutics, who aim to discover medicines that extend healthy lifespan, based on insights into the biochemical Hallmarks of Aging

19.45             Company presentation Dr Daniel Ives, CEO & Founder, Shift Bioscience, who are targeting the root causes of aging to extend healthy lifespan

20.00              Company Presentation - Professor Joanna Holbrook, VP of Bioinformatics, Cambridge Epigenetix
20.15             Q&A with audience and speakers
20.30             Networking over drinks and nibbles
21.00             Evening ends


Registration Type Ticket Price
OBN / OneNucleus Member One Complimentary
OBN/ON Member Additional Ticket £25*
PhD Students & Scientists Complimentary
OBN Non-Member £50*
* Prices shown do not include VAT (charged at 20%)


Cancellation charges will apply. All cancellations must be made in writing either by letter or email to events@obn.org.uk.

Please see our Terms and Conditions.

Kindly sponsored by:

Kindly co-promoted by:
Organisers   Contact    
OBN (UK) Ltd
5F Park Square
Milton Park
OX14 4RR
General Enquiries
T: +44 (0)1235 420870

© 2019, All Rights Reserved. OBN (UK) Ltd. Is A Limited Company Registered In England & Wales, Company No. 06618658. VAT No. 935 2567 09
Processing. Please wait.